B-cell-targeted therapy in systemic vasculitis

Current Opinion in Rheumatology

Volumn 28, Issue 1, 2016, Pages 15-20

  Lally, Lindsay ^a   Spiera, Robert ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Antineutrophil cytoplasmic autoantibody; Associated vasculitis; B cells; Cryoglobulinemic vasculitis; Rituximab

Indexed keywords

AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; RITUXIMAB; IMMUNOLOGIC FACTOR;

AORTA ARCH SYNDROME; B LYMPHOCYTE; CRYOGLOBULINEMIC VASCULITIS; EOSINOPHILIC GRANULOMA; FOLLOW UP; HUMAN; MICROSCOPIC POLYANGIITIS; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC VASCULITIS; TARGET CELL; WEGENER GRANULOMATOSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHURG-STRAUSS SYNDROME; CRYOGLOBULINEMIA; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; TAKAYASU ARTERITIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B-LYMPHOCYTES; CHURG-STRAUSS SYNDROME; CRYOGLOBULINEMIA; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOLOGIC FACTORS; MICROSCOPIC POLYANGIITIS; MOLECULAR TARGETED THERAPY; RITUXIMAB; SYSTEMIC VASCULITIS; TAKAYASU ARTERITIS;

EID: 84948661705     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000235     Document Type: Review

References (35)

1. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70:488-494.
2. Hoffman GS, Kerr GS, Leavitt RY, et al. 1992. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
3. Cupps TR, Edgar LC, Fauci AS. Suppressionof human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128:2453-2457.
4. Chen M, Kallenberg CG. ANCA-associated vasculitides-advances in pathogenesis and treatment. Nat Rev Rheumatol 2010; 6:653-664.
5. Stone JH, Merkle PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
6. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
7. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417-427.
8. Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomized trial. Ann Rheum Dis 2015; 74:1178-1182.
9. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371:1771-1780.
10. Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013; 65:2441-2449.
11. Miloslavsky EM, Specks U, Merkel PA, et al. Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2014; 66:3151-3159.
12. Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des DevelTher 2015; 9:333-347.
13. Holle J, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis: comparison of efficacy in granulomatous versus vasculitic manifestation. Ann Rheum Dis 2012; 71:327-333.
14. Aries PM, Hellmich B, Voswinkel JK, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-885.
15. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's with refractory granulomatous manifestations. J Rheum 2008; 35:2017-2023.
16. Martinez DP, Chaudhry A, Jones RB, et al. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009; 34:328-335.
17. Lally L, Lebovics RS, Huang WT, Spiera RF. Effectiveness of rituximab for the otolaryngologic manifestations of granulomatosis with polyangiitis (Wegener's). Arthritis Care Res 2014; 66:1403-1409.
18. Cartin-Ceba R, Golbin J, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): a single-center ten-year experience. Arthritis Rheum 2012; 64:3770-3778.
19. Smith RM, Jones RB, Guerry M, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:3760-3769.
20. Calich AL, Puéchal X, Pugnet G, et al. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegeners). Results of a single-center cohort study on 66 patients. J Autoimmun 2014; 50:135-141.
21. Clinicaltrials.govINCT01697267. Published August 31, 2012. Updated September 4, 2015. Accessed September 11, 2015.
22. Terier B, Pagnoux C, Arras A, et al. Rituximab versus azathioprine for maintenance in antineutrophile cytoplasmic antibodies (ANCA)-associated vasculitis (MAINRITSAN): follow-up at 34 months. La PresseMedicale 2013; 42:; abtstract P230.
23. Clinicaltrials.gov/NCT01731561. Published October 12, 2012. Updated April 29, 2015. Accessed September 11, 2015.
24. Alberici F, Smtih RM, Jones RB, et al. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 2015; 54:1153-1160.
25. Roberts DM, Jones RB, Smith RM, et al. Rituximab-assoicatedhypogamma-globulinemia: incidence, predictors and outcomes in patients with multi-systemi autoimmune disease. J Autoimmun 2015; 57:60-65.
26. Mohammad AJ, Hot A, Arndt F, et al. Rituximab for the treatment of eosino-philic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 2014. [Epub ahead of print]
27. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843-853.
28. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglo-bulinemic vasculitis. Arthritis Rheum 2012; 64:835-842.
29. Quartuccio L, Zuliani F, Corazza L, et al. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study. J Autoimmun 2015. [Epub ahead of print]
30. Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: phase II clinical trial and systematic review. Autoimmun Rev 2015. [Epub ahead of print]
31. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res 2010; 62:1787-1795.
32. Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterized by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012; 71:75-79.
33. Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced takayasu arteritis using rituximab. Case Rep Rheumatol 2012. [Epub ahead of print]
34. Caltran E, Di Colo G, Ghigliotti G, et al. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 2014; 33:1183-1184.
35. Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheu-matol 2014; 26:7-14.